Nuvalent
time on treatment sustained duration with follow up ongoing phase i a a a a prior alk including prior alk no and subsequently confirmed pending confirmation pep all patients tumor response remain without disease progression response evaluable patients continue median range of months median range to response weeks months data as of august for response evaluable patients progressive disease partial response once daily tyrosine kinase inhibitor source lin | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
22 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
time on treatment sustained duration with follow up ongoing phase i a a prior alk including prior alk no and subsequently confirmed pending confirmation all patients tumor response remain without disease progression response evaluable patients continue median range of months median range to response weeks months data as of august for response evaluable patients progressive disease partial response once daily tyrosine kinase inhibitor source lin | Nuvalent
Investor Presentation
February 2024
time on treatment sustained duration with follow up ongoing phase i a a prior alk including prior alk no and subsequently confirmed pending confirmation all patients tumor response remain without disease progression response evaluable patients continue median range of months median range to response weeks months data as of august for response evaluable patients progressive disease partial response once daily tyrosine kinase inhibitor source lin | Nuvalent
Investor Presentation
January 2024
time on treatment sustained duration with follow up ongoing phase i a a a a prior alk including prior alk no and subsequently confirmed pending confirmation pep all patients tumor response remain without disease progression response evaluable patients continue median range of months median range to response weeks months data as of august for response evaluable patients progressive disease partial response once daily tyrosine kinase inhibitor source lin i | Nuvalent
Investor Presentation
November 2023
time on treatment sustained duration with follow up ongoing a | Nuvalent
Related slides by other companies
Genelux
Investor Presentation
October 2023
demonstrated deep and durable tumor shrinkage | Genelux
Genelux
Investor Presentation
February 2024
demonstrated deep and durable tumor shrinkage | Genelux
Genelux
Investor Presentation
July 2023
demonstrated deep and durable tumor shrinkage | Genelux
Genelux
Investor Presentation
December 2023
demonstrated deep and durable tumor shrinkage | Genelux
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io